Vanguard Global Advisers’s Sanara MedTech SMTI Stock Holding History

Vanguard Global Advisers’s Portfolio SMTI Stock Details SMTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.3K	Hold	905	–	–	﹤0.01%	3309
2026 Q1	$15.5K	Buy	+905	New	+$18.6K	﹤0.01%	3388

Other funds holding SMTI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

SWM

Stonebridge Wealth Management Oak Brook, Illinois $112M AUM 23.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Global Advisers's SMTI Position: Q2 2026 in Review

Vanguard Global Advisers held its Sanara MedTech (SMTI) position steady in Q2 2026 at 905 shares worth $21.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3309.

Vanguard Global Advisers first reported a position in SMTI in Q1 2026 and has held it in 2 quarters since. 70 funds tracked by Wall St. Rank hold SMTI as of Q2 2026.

Vanguard Global Advisers held 905 shares of Sanara MedTech worth $21.3K as of Q2 2026.
Vanguard Global Advisers left its Sanara MedTech share count unchanged in Q2 2026.
Sanara MedTech made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3309 holding.
Vanguard Global Advisers first reported a position in Sanara MedTech in Q1 2026 and has held it in 2 quarters since.
70 funds tracked by Wall St. Rank held Sanara MedTech as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.